A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT05171075
Trial Phases:	Phase III	Protocol IDs:	ANT-008 (primary) NCI-2022-08854 2021-003085-12
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Anthos Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05171075

Summary

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of
abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in
patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Objectives

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by
high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding.
Patients with intact GI and GU cancer have increased bleeding risk with oral direct
anticoagulants (DOACs), Guidelines advice caution with those DOACs or state preference for
low molecular weight heparin (LMWH) in this population. The ANT-008 study will compare
treatment with abelacimab monthly administration to LMWH daily subcutaneous (sc)
administration over 6-month treatment. The study outcomes include VTE recurrence, bleeding
event and treatment discontinuation at 6 months

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.